Seres Therapeutics, Inc. (NASDAQ:MCRB) – Leerink Swann raised their FY2017 earnings per share (EPS) estimates for shares of Seres Therapeutics in a note issued to investors on Wednesday. Leerink Swann analyst J. Schwartz now expects that the biotechnology company will post earnings per share of ($2.24) for the year, up from their prior forecast of ($2.30). Leerink Swann also issued estimates for Seres Therapeutics’ Q4 2017 earnings at ($0.75) EPS, FY2018 earnings at ($2.48) EPS and FY2019 earnings at ($2.25) EPS.
Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.22. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. The company had revenue of $23.00 million for the quarter, compared to analyst estimates of $17.29 million. During the same period last year, the company earned ($0.46) earnings per share. The business’s revenue was up 76.9% compared to the same quarter last year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://ledgergazette.com/2017/11/15/fy2017-eps-estimates-for-seres-therapeutics-inc-raised-by-analyst-mcrb.html.
A number of other research firms have also commented on MCRB. BidaskClub lowered Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Zacks Investment Research lowered Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Canaccord Genuity set a $20.00 price objective on Seres Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Cowen and Company reiterated a “buy” rating on shares of Seres Therapeutics in a research note on Monday, October 2nd. Finally, Cantor Fitzgerald reiterated a “buy” rating on shares of Seres Therapeutics in a research note on Wednesday, August 30th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $18.00.
Seres Therapeutics (NASDAQ:MCRB) opened at $9.52 on Monday. Seres Therapeutics has a 1-year low of $8.85 and a 1-year high of $17.42. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.11.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in Seres Therapeutics by 1.2% during the second quarter. Vanguard Group Inc. now owns 1,585,026 shares of the biotechnology company’s stock valued at $17,911,000 after acquiring an additional 19,363 shares during the period. Ark Investment Management LLC increased its stake in Seres Therapeutics by 21.5% during the second quarter. Ark Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock valued at $8,647,000 after acquiring an additional 135,276 shares during the period. JPMorgan Chase & Co. increased its stake in Seres Therapeutics by 39.9% during the third quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock valued at $6,160,000 after acquiring an additional 106,479 shares during the period. State Street Corp increased its stake in Seres Therapeutics by 12.0% during the second quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock valued at $3,637,000 after acquiring an additional 34,393 shares during the period. Finally, Northern Trust Corp increased its stake in Seres Therapeutics by 16.2% during the second quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock valued at $2,664,000 after acquiring an additional 32,875 shares during the period. Hedge funds and other institutional investors own 74.77% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.